INTERCEPT

DEVICE2 trials

Sponsors

Cerus Corporation, Swiss Transfusion SRC

Conditions

Anemia

Phase 3

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

CompletedNCT03459287

Cerus CorporationAnemia

Start: 2018-12-05End: 2024-03-05Updated: 2025-09-10

Unknown Phase

INTERCEPT Safety Evaluation in Anemic Patients

WithdrawnNCT03486054

Swiss Transfusion SRCAnemia

Start: 2019-06-30End: 2020-06-30Updated: 2019-12-13

Related Papers

Characterizing the antibody response to amustaline/glutathione pathogen‐reduced red blood cells

Transfusion2024-12-254 citations

Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial

Blood2024-11-05

Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).

2024-03-2211 citations